Es involved in aIIbb3 integrin signalling, such as FAK, Src, and p85 subunit of PI3-Kinase in platelets isolated from the experimental groups. Compared to C group, the densitometric analysis of immunoblots presented that the pFAK/FAK ratio was increased by ,7.1fold at HH group, ,1.88-fold at HHin-EPCs, ,1.66-fold at HHfin-EPCs, ,7.95-fold at Rubusoside cost HH-PMPs and ,6.98-fold at the platelets isolated from HH-EPCs-PMPs group (n = 4, Fig. 2A). Compared to HH group, in HHin-EPCs and HHfin-EPCs groups, the values for pFAK/FAK ratio were reduced by ,3.78-fold, andResults Assessment of Biochemical Parameters and of Hypertension in the Animal ModelCompared to normal hamsters in group C that displayed values of cholesterol and triglyceride concentrations (154.5568.74 mg/Platelets, EPCs and AtherosclerosisFigure 1. The flow cytometric detection on platelet activated Integrin b- 3 (1): control group, C (2): hypertensive- hypercholesterolemic (HH) 16574785 group; (3): prevention group, HHin-EPCs (4) regression group, HHfin-EPCs (5) HH treated with PMPs group, HH-PMPs and (6) HH treated with EPCsPlatelets, EPCs and Atherosclerosisand PMPs, HH-EPCs-PMPs. The left panel (A): representative unmarked sample; the right panel (B): representative sample marked with Integrin b3 antibody. The marked events for Integrin b3 are illustrated in gates R7. doi:10.1371/journal.pone.0052058.g,4.3-fold respectively (p#0.05). Compared to C group, the protein expression of PI3K was higher by ,2.4-fold in HH group, ,1.5-fold in HHin-EPCs, ,1.1-fold in HHfin-EPCs, ,3.7-fold in HH-PMPs and ,2.46-fold in HH-EPCs-PMPs group (n = 4, Fig. 2B). Compared to HH group, in HHin-EPCs, and HHfinEPCs the values for PI3K were reduced by ,1.6-fold, and by ,2.19-fold, respectively (p#0.05). The Western blotting experiments for src showed similar results, with a significant raise in its expression in HH and HH-PMPs groups, vs. C group. Thus, the increase in p-src/src ratio was by ,2.68-fold in platelets isolated from HH group, and by ,2.96-fold in platelets isolated from HHPMPs group (n = 4, Fig. 2C); the augmentation measured ,1.33fold in HHin-EPCs group, ,1.19-fold in HHfin-EPCs and ,2.56fold in platelets isolated from HH-EPCs-PMPs group (n = 6, Fig. 2C). Compared to HH group, in HHin-EPCs and HHfinEPCs groups, the values for p-src/src ratio were reduced by ,2.02-fold and by ,2.25-fold, respectively (p#0.05). Moreover, compared to HH group, the value for pFAK/FAK, PI3K and psrc/src ratio were augmented by ,1.12-fold, ,1.54-fold, and ,1.1-fold in platelets isolated from HH-PMPs group, and were not significantly changed in platelets from HH-EPCs-PMPs group. Taken together, these data demonstrate that EPC treatment (both in prevention and in regression situation) modulates the platelet signaling protein expression, and reduces their activation towards the values recorded in controls. The levels of analyzed proteins recorded in the HH-PMPs group were significantly enhanced (p#0.05), compared to C group; administration of EPCs together with PMPs reduces the values compared to HH-PMPs group, but is not so efficient as EPC administration, only.Evaluation of Cytokine/Chemokines and Growth Factors in Supernatants of Activated BI-78D3 PlateletsThe activation of platelets results in the release of various cytokines, which might be able to exert putative effects on EPC functions in a paracrine manner. Therefore, we measured the concentration of several cytokine/chemokines and growth factors in the supernatant of platelets a.Es involved in aIIbb3 integrin signalling, such as FAK, Src, and p85 subunit of PI3-Kinase in platelets isolated from the experimental groups. Compared to C group, the densitometric analysis of immunoblots presented that the pFAK/FAK ratio was increased by ,7.1fold at HH group, ,1.88-fold at HHin-EPCs, ,1.66-fold at HHfin-EPCs, ,7.95-fold at HH-PMPs and ,6.98-fold at the platelets isolated from HH-EPCs-PMPs group (n = 4, Fig. 2A). Compared to HH group, in HHin-EPCs and HHfin-EPCs groups, the values for pFAK/FAK ratio were reduced by ,3.78-fold, andResults Assessment of Biochemical Parameters and of Hypertension in the Animal ModelCompared to normal hamsters in group C that displayed values of cholesterol and triglyceride concentrations (154.5568.74 mg/Platelets, EPCs and AtherosclerosisFigure 1. The flow cytometric detection on platelet activated Integrin b- 3 (1): control group, C (2): hypertensive- hypercholesterolemic (HH) 16574785 group; (3): prevention group, HHin-EPCs (4) regression group, HHfin-EPCs (5) HH treated with PMPs group, HH-PMPs and (6) HH treated with EPCsPlatelets, EPCs and Atherosclerosisand PMPs, HH-EPCs-PMPs. The left panel (A): representative unmarked sample; the right panel (B): representative sample marked with Integrin b3 antibody. The marked events for Integrin b3 are illustrated in gates R7. doi:10.1371/journal.pone.0052058.g,4.3-fold respectively (p#0.05). Compared to C group, the protein expression of PI3K was higher by ,2.4-fold in HH group, ,1.5-fold in HHin-EPCs, ,1.1-fold in HHfin-EPCs, ,3.7-fold in HH-PMPs and ,2.46-fold in HH-EPCs-PMPs group (n = 4, Fig. 2B). Compared to HH group, in HHin-EPCs, and HHfinEPCs the values for PI3K were reduced by ,1.6-fold, and by ,2.19-fold, respectively (p#0.05). The Western blotting experiments for src showed similar results, with a significant raise in its expression in HH and HH-PMPs groups, vs. C group. Thus, the increase in p-src/src ratio was by ,2.68-fold in platelets isolated from HH group, and by ,2.96-fold in platelets isolated from HHPMPs group (n = 4, Fig. 2C); the augmentation measured ,1.33fold in HHin-EPCs group, ,1.19-fold in HHfin-EPCs and ,2.56fold in platelets isolated from HH-EPCs-PMPs group (n = 6, Fig. 2C). Compared to HH group, in HHin-EPCs and HHfinEPCs groups, the values for p-src/src ratio were reduced by ,2.02-fold and by ,2.25-fold, respectively (p#0.05). Moreover, compared to HH group, the value for pFAK/FAK, PI3K and psrc/src ratio were augmented by ,1.12-fold, ,1.54-fold, and ,1.1-fold in platelets isolated from HH-PMPs group, and were not significantly changed in platelets from HH-EPCs-PMPs group. Taken together, these data demonstrate that EPC treatment (both in prevention and in regression situation) modulates the platelet signaling protein expression, and reduces their activation towards the values recorded in controls. The levels of analyzed proteins recorded in the HH-PMPs group were significantly enhanced (p#0.05), compared to C group; administration of EPCs together with PMPs reduces the values compared to HH-PMPs group, but is not so efficient as EPC administration, only.Evaluation of Cytokine/Chemokines and Growth Factors in Supernatants of Activated PlateletsThe activation of platelets results in the release of various cytokines, which might be able to exert putative effects on EPC functions in a paracrine manner. Therefore, we measured the concentration of several cytokine/chemokines and growth factors in the supernatant of platelets a.
